Forecast Ledgerinterventional psychiatry and psychedelic medicineQuoted, dated predictions scored against public outcomes under one written method. Every score links to the words, the rule and the evidence.

Void · Condition unmet

Rules 1.1.0 · as of 14 Sep 2026

Quote

“If we succeed, and if we medicalise psychedelics, ATAI will be a double-, triple-digit billion-dollar company.”
· Meet the crypto-pioneering, biohacking, psychedelic-promoting billionaire who wants to reimagine the Olympics (Forbes, W. Yakowicz; text verified via Forbes Australia reprint of 2024-08-03) · interview

atai would be worth US$10B to US$100B+ once psychedelics are medicalised.

Intake

EventA proposition written from a template on the asset, with a resolution criterion and a named public source, before the outcome is looked up. The same event resolves every person's items on it. Method ›
atai Life Sciences market capitalization at or above US$10 billion
AreaOne of five topic classes: regulatory decisions, clinical trial outcomes, company and market outcomes, payer and policy, practice adoption. Every event has one area. Method ›
Company and market outcomes
DeadlineThe date by which the event must happen for the item to be true. It comes only from the person's words through the anchor table. Method ›
None stated · undated panelItems with no deadline in the person's words, scored on a uniform 24-month window from the statement date. Part of the headline panel since rules 1.1.0; also shown on its own. Method ›, 24-month window to 31 Jul 2026
Probability
0.90 LexiconThe fixed five-bin table that turns a phrase into a probability. The strongest phrase in the claim sentence decides; coders never read tone. Method › · binOne of five lexicon steps: A 'will' 0.90, B 'probably' 0.70, C 'may' 0.50, D 'unlikely' 0.30, E 'never' 0.10. A stated number goes to the nearest bin for calibration only. Method › A · “will be”
Base rateThe probability a published external study gives an event of that class and stage, fixed at intake. Halved when the item window is shorter than the class median time to decision. Never learned from the ledger's own items. Method ›
None in the table
Tags
conditional, affiliated, retrospective
Coder BCohen's kappa: agreement between two coders beyond chance, from -1 to 1. Reported for admit, event, deadline, bin and asserts from the second-coder match test. Method ›
admittedA statement that passed intake: sincere, the person's own claim, forward-looking, inside the five areas, and not excluded by a reason code. Only admitted statements become items. Method › · event E-0028 · deadline none · bin A
Registry entry

The market capitalization of atai Life Sciences (Nasdaq: ATAI, or its successor listing) is at or above US$10 billion at a market close, per Nasdaq closing price and shares outstanding in SEC filings.

Resolved on the named data series only: the market capitalization of atai Life Sciences (Nasdaq: ATAI, or its successor listing), computed as the Nasdaq closing share price multiplied by the shares outstanding stated on the cover page of atai's most recent periodic SEC filing on EDGAR. TRUE on the first trading day on which that closing market capitalization is at or above US$10 billion. The threshold is in the forecaster's words, so it resolves as binary at US$10 billion with no band. FALSE at the deadline when no market close has reached US$10 billion. If the shares stop trading with no successor listing and no price series has published 12 months after the deadline, the event is unresolvable. Realized values are stored, not scored.

Resolution source: Nasdaq closing price for ATAI and shares outstanding in atai Life Sciences periodic filings on SEC EDGAR

Readings: 'double-, triple-digit billion-dollar company' = market capitalization of at least USD 10 billion; the range's lower bound is the threshold.

How to read
The event, criterion and deadline were written at intake, before the outcome1 if the registry event happened on or before the item's deadline, 0 if it did not. Written by a resolver who never sees p. Method › was looked up. Coder B coded the statement independently.

Coder C

Resolution

State
VoidAn item that cannot be scored: the coders disagreed (AMBIGUOUS), the condition was unmet, or the source never published (UNRESOLVABLE). Counted, never scored. Method ›
Effective deadlineAn item enters the score only when its deadline has passed and the outcome is true or false. A claim already known true still waits for its deadline. Method ›
31 Jul 2026
Outcome1 if the registry event happened on or before the item's deadline, 0 if it did not. Written by a resolver who never sees p. Method ›
not occurred · checked through 13 Sep 2026
Resolver note
Series: Nasdaq close multiplied by the share count on the latest 10-Q cover (370,864,669 as of 2026-08-07). The highest close in the final months of trading was $7.44 on 2026-08-25, giving $2.76B (stored as realized_value); the last closes before Lilly's $6.75-cash-plus-CVR takeover closed on 2026-09-11 were $7.35 (2026-09-10 and 09-11), giving $2.73B. Earlier history is far lower: IPO-day cap $2.29B on 2021-06-18 and year-end caps of $1.22B (2021), $0.44B (2022), $0.23B (2023), $0.22B (2024) and $1.49B (2025). No close ever reached $10B. Closing prices come from Yahoo Finance and Stock Analysis, which both report Nasdaq closes (nasdaq.com timed out). ATAI stopped trading after the acquisition with no successor listing, so no later close can change this result.
BrierThe squared gap between a probability and the outcome, (p - o)^2. 0 is perfect, 0.25 is the constant coin flip, 1 is confidently wrong. Lower is better. Method ›
Not scored
How to read
State at window close; the outcome comes from the registry, the score from the rule.

Registry

Receding horizon

Angermayer promised atai Life Sciences market capitalization at or above US$10 billion 3 times; it has not happened.

promised datehappened
20232024202520262027202820292023202420252026202720282029TODAY2022-11-16: by 2026-11-16 · p 0.502024-07-31: by 2026-07-31 · p 0.902025-10-24: by 2028-10-24 · p 0.50X SAID ON · Y PROMISED BY · DASHED: PROMISED = SAID · DOT AREA = P

Cluster E-0028

Timeline

1 claim against 40 events in the field.

saiddueevent
12 Aug 2024 · Neuronetics / Greenbrook TMS: Neuronetics agrees an all-stock merger with Greenbrook TMS, the largest US TMS c13 Aug 2024 · MindMed: MindMed closes a $75M public offering, bringing 2024 gross equity raises to abou15 Aug 2024 · Lykos Therapeutics: Lykos cuts about 75% of its roughly 100 staff after the CRL and retractions; fou5 Sep 2024 · Lykos Therapeutics: Lykos CEO Amy Emerson steps down; COO Michael Mullette becomes interim CEO and D31 Oct 2024 · Compass Pathways: Compass delays COMP005 topline to Q2 2025 and COMP006 data to after the 26-week 15 Nov 2024 · Numinus Wellness / Stella: Numinus agrees to sell its five Utah wellness clinics to Stella MSO and pivots t9 Dec 2024 · Neuronetics / Greenbrook TMS: Neuronetics completes the Greenbrook TMS merger, becoming a vertically integrate17 Dec 2024 · Numinus Wellness / Stella: Numinus closes the sale of its US clinics to Stella and launches a data-sharing 10 Jan 2025 · Lykos Therapeutics / Antonio Gracias: Billionaire investor Antonio Gracias moves to take control of Lykos with about $13 Jan 2025 · Johnson & Johnson / Intra-Cellular Therapies: J&J agrees to acquire Intra-Cellular Therapies (Caplyta) in its largest neurosci15 Jan 2025 · Lykos Therapeutics: Five Lykos board directors depart as the company seeks new funding after the FDA22 Jan 2025 · Johnson & Johnson (Spravato): J&J Q4 2024 results show Spravato crossed $1B in annual sales for the first time30 May 2025 · Lykos Therapeutics: Lykos completes the first close of a Series B co-led by the Gracias Family Found2 Jun 2025 · atai Life Sciences / Beckley Psytech: atai agrees an all-share combination with Beckley Psytech, contingent on BPL-00316 Jun 2025 · Supernus Pharmaceuticals / Sage Therapeutics: Supernus agrees to acquire Sage Therapeutics (Zurzuvae) after Sage rebuffed Biog23 Jun 2025 · Compass Pathways: Compass shares fall sharply as investors judge the 3.6-point COMP005 effect size30 Jun 2025 · Cybin: Cybin announces a financing of up to $500M in convertible debentures to fund its20 Aug 2025 · Lykos Therapeutics: Lykos names former Point72 capital markets head Nick McEntire as president under28 Aug 2025 · Lykos Therapeutics / Resilient Pharmaceuticals: Lykos Therapeutics rebrands as Resilient Pharmaceuticals following the Gracias-l22 Oct 2025 · Mindbloom: A wrongful-death lawsuit is filed against at-home ketamine provider Mindbloom ov31 Oct 2025 · MindMed: MindMed closes an upsized underwritten public offering after positive phase 3 pl5 Nov 2025 · AtaiBeckley: atai and Beckley Psytech complete their combination to form AtaiBeckley; a $150M19 Nov 2025 · Done Global: A federal jury convicts Done founder Ruthia He and clinical president David Brod17 Dec 2025 · Done Global: A federal grand jury indicts Done Global itself over the alleged $100M Adderall 5 Jan 2026 · Cybin / Helus Pharma: Cybin rebrands as Helus Pharma and moves its US listing to Nasdaq under ticker H12 Jan 2026 · MindMed / Definium Therapeutics: MindMed rebrands as Definium Therapeutics (Nasdaq: DFTX from Jan 15) and guides 21 Jan 2026 · Johnson & Johnson (Spravato): J&J full-year 2025 results show Spravato sales of about $1.7B, with Q4 2025 up 618 Feb 2026 · Compass Pathways: Compass prices a $150M public offering the day after COMP006 topline; with warra1 Mar 2026 · Alto Neuroscience: Alto closes a $120M private placement led by Commodore Capital at $20 per share,17 Mar 2026 · Neuronetics: Neuronetics appoints Dan Reuvers as CEO as 2025 revenue nearly doubles after the7 Apr 2026 · Neuronetics: Neuronetics' top shareholder says the company has 'chronically underperformed' a29 Apr 2026 · GH Research: GH Research prices a $117.5M underwritten offering at $18 per share to fund the 13 May 2026 · Compass Pathways: Compass Q1 2026 update: rolling NDA sections already submitted, final submission25 Jun 2026 · Definium Therapeutics: Definium closes an upsized $805M public offering at $34 per share three days aft25 Jun 2026 · Helus Pharma: Helus completes a $50M underwritten offering, lifting cash to about $207M ahead 8 Jul 2026 · Done Global: Done founder Ruthia He is sentenced to 72 months in prison and fined $90M for th15 Jul 2026 · Johnson & Johnson (Spravato): J&J Q2 2026 results show Spravato sales of $584M, up 25% quarter over quarter an16 Jul 2026 · Eli Lilly / AtaiBeckley: Lilly agrees to acquire AtaiBeckley for $6.75 per share cash plus a CVR of up to3 Aug 2026 · Helus Pharma: Helus Pharma appoints Michael Halstead as chief executive officer ahead of its p11 Sep 2026 · Eli Lilly / AtaiBeckley: Eli Lilly completes its acquisition of AtaiBeckley, taking BPL-003 and VLS-01 inELI LILLY / ATAIBECKLEY: ELI LILLY COMPLETES ITS ACQUISITION OF ATAIBECKLEY, TAKING BPL-003 AND VLS-01 INATAI LIFE SCIENCE…atai Life Sciences market capitalization at or above US$10 billion · stated 31 Jul 2024atai Life Sciences market capitalization at or above US$10 billion · restated 31 Jul 2024 · p 90%atai Life Sciences market capitalization at or above US$10 billion · void 31 Jul 202690%TODAY20252026

Company and market outcomes